Lumos Pharma, Inc. (LUMO) |
| 4.34 0 (0%) 12-11 16:00 |
| Open: | 4.33 |
| High: | 4.34 |
| Low: | 4.33 |
| Volume: | 390,873 |
| Market Cap: | 38(M) |
| PE Ratio: | -1.01 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 10.33 |
| Resistance 1: | 8.84 |
| Pivot price: | 7.39 |
| Support 1: | 7.28 |
| Support 2: | 6.32 |
| 52w High: | 4.5756 |
| 52w Low: | 1.3701 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Financials
| EPS | -1.750 |
| Book Value | -1.090 |
| PEG Ratio | 0.00 |
| Gross Profit | 5.647 |
| Profit Margin (%) | -14.02 |
| Operating Margin (%) | -5.98 |
| Return on Assets (ttm) | -0.6 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 24 Apr 2025
Lumos Pharma Stock Price, News & Analysis - Stock Titan
Thu, 12 Dec 2024
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance
Thu, 24 Oct 2024
DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology
Wed, 23 Oct 2024
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - Yahoo Finance
Wed, 22 May 2024
Sarah Alexander Net Worth (2026) - GuruFocus
Sun, 04 Dec 2022
Bradley J Powers Net Worth (2026) - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
